Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment

Lulu Xue(University of Pennsylvania), Ningqiang Gong(University of Pennsylvania), Sarah J. Shepherd(University of Pennsylvania), Xinhong Xiong(University of Electronic Science and Technology of China), Xueyang Liao(Children's Hospital of Philadelphia), Xuexiang Han(University of Pennsylvania), Gan Zhao(University of Pennsylvania), Chao Song(Children's Hospital of Philadelphia), Xisha Huang(University of Pennsylvania), Hanwen Zhang(University of Pennsylvania), Marshall S. Padilla(University of Pennsylvania), Jingya Qin(University of Pennsylvania), Yi Shi(University of Delaware), Mohamad‐Gabriel Alameh(University of Pennsylvania), Darrin J. Pochan(University of Delaware), Karin Wang(Temple University), Fanxin Long(Children's Hospital of Philadelphia), Drew Weissman(University of Pennsylvania), Michael J. Mitchell(California Institute for Regenerative Medicine)
Journal of the American Chemical Society
May 26, 2022
Cited by 166

Abstract

The development of lipid nanoparticle (LNP) formulations for targeting the bone microenvironment holds significant potential for nucleic acid therapeutic applications including bone regeneration, cancer, and hematopoietic stem cell therapies. However, therapeutic delivery to bone remains a significant challenge due to several biological barriers, such as low blood flow in bone, blood–bone marrow barriers, and low affinity between drugs and bone minerals, which leads to unfavorable therapeutic dosages in the bone microenvironment. Here, we construct a series of bisphosphonate (BP) lipid-like materials possessing a high affinity for bone minerals, as a means to overcome biological barriers to deliver mRNA therapeutics efficiently to the bone microenvironment in vivo. Following in vitro screening of BP lipid-like materials formulated into LNPs, we identified a lead BP-LNP formulation, 490BP-C14, with enhanced mRNA expression and localization in the bone microenvironment of mice in vivo compared to 490-C14 LNPs in the absence of BPs. Moreover, BP-LNPs enhanced mRNA delivery and secretion of therapeutic bone morphogenetic protein-2 from the bone microenvironment upon intravenous administration. These results demonstrate the potential of BP-LNPs for delivery to the bone microenvironment, which could potentially be utilized for a range of mRNA therapeutic applications including regenerative medicine, protein replacement, and gene editing therapies.


Related Papers

No related papers found

Powered by citation graph analysis